HSIC

Business profile & competitive position

Henry Schein, Inc. operates as a healthcare solutions company under the Healthcare sector’s Medical – Distribution industry classification. Its business is organized into three reportable segments: Global Distribution and Value-Added Services, which supplies dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and related services; Global Specialty Products, which makes and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products; and Global Technology, which sells practice-management software, e-services, and other technology-enabled tools for healthcare providers. The bulk of its revenue still comes from moving physical product to office-based dental and medical practitioners, so its economics look more like a scaled distributor than a high-margin manufacturer.

The numbers bear that out. The net margin is 3.0%, which is unusually thin by healthcare standards but typical for a high-volume distributor that competes on selection, delivery reliability, and customer reach. The return on equity is 12.4%, meaning the company is converting those thin margins into a mid-teens return for shareholders through asset turnover and leverage on its logistics base. That 12.4% ROE, combined with 38 distribution centers covering more than 5.4 million square feet and an average shipment volume of roughly 150,000 cartons per day, suggests the core moat is operational scale rather than pricing power. It also maintains 17 manufacturing facilities covering 0.6 million square feet and an equipment sales-and-service network of 127 centers worldwide. The Technology segment had an active user base of about 95,000 practices and 324,000 consumers as of December 27, 2025, adding a recurring-software layer, but the financial profile still ties closely to office-visit volumes and merchandise throughput.

Financial posture

At a $9.7 billion market capitalization and a trailing P/E of 25.0, Henry Schein is priced like a stable compounder rather than a deep-value distributor. The 25.0 P/E is a notable premium to the 3.0% net margin, which tells you the market is paying for consistency, scale, and the expectation that revenue turns over reliably even when per-dollar profitability is low. The 12.4% ROE supports that narrative: it is above the cost of capital for most healthcare distributors and indicates the balance sheet and operational intensity are working together.

Beta sits at 0.86, less than the market’s 1.0, which fits the defensive, non-cyclical label often attached to medical distribution. The stock has historically moved less violently than the broad market, consistent with a business tied to recurring office-supply demand rather than discretionary spending. What the valuation does not show is explosive growth potential from the existing margin structure alone; with only 3.0 cents of net income per dollar of sales, incremental earnings have to come from volume, mix shift toward higher-margin specialty products and software, or cost leverage.

Strategic priorities & outlook

In its most recent 10-K filing, Henry Schein outlined four operational priorities that frame the near-term outlook. First, the company aims to build complementary software, specialty, and services businesses for “high growth” under the BOLD+1 plan. Second, it is working to operationalize “One Distribution,” an initiative intended to improve customer experience, increase efficiency, and support growth from a unified fulfillment backbone. Third, the “One Schein” program is meant to broaden and deepen customer relationships across segments. Fourth, management is pushing digital transformation for both customers and for Henry Schein itself.

Those priorities align with the financial profile: a 3.0% net margin leaves little room for inefficiency, so “One Distribution” and internal digitization are likely aimed at cost-to-serve. Meanwhile, software and specialty products are the logical places to improve mix, since they carry more recurring revenue and higher margin potential than commodity distribution. The 10-K also highlighted infrastructure scale—more than 300,000 stocked products and the 5.4 million square-foot distribution footprint—which is the platform these initiatives are built on.

Macro & geopolitical exposure

As a Healthcare / Medical – Distribution company, Henry Schein is exposed to the regulatory and reimbursement environment that governs office-based dental and medical care. Changes in Medicare, Medicaid, or commercial reimbursement rates can influence how often practitioners purchase equipment and supplies. The pharmaceutical, vaccine, and infection-control portions of the catalog are sensitive to drug pricing policy and public-health procurement trends. Tariffs or trade restrictions on imported medical devices, gloves, masks, and equipment could matter because global sourcing is common across distributors in this space. Currency exposure is also relevant: “Global” segments imply cross-border revenue and sourcing, so dollar strength or weakness can affect translated results and competitiveness. Finally, supply-chain reliability—freight costs, inventory carrying costs, and last-mile delivery—directly affects a 3.0% margin business, making logistics inflation or disruption a persistent risk.

Recent developments

The news flow heading into the next report is focused on the upcoming third-quarter 2026 release. On October 20, 2026, Businesswire announced that Henry Schein will webcast its Q3 2026 conference call on November 3, 2026, at 8:00 a.m. ET. On October 27, 2026, Zacks published two pieces: one noting that analysts estimate Henry Schein will report a decline in earnings, and another preview of what investors should watch. Then on October 30, 2026, Zacks also featured Henry Schein as a top momentum stock for the long term. That creates an interesting tension heading into the print: exercise caution on near-term earnings pressure, yet acknowledge the longer-term momentum narrative. The next report is scheduled for November 3, 2026, before the market open, with a current consensus EPS estimate of $1.36.

Earnings behavior & post-earnings drift

Henry Schein has a solid beat record over the last eight reported quarters, beating earnings estimates in six of them for a 75% beat rate. The average earnings surprise across those quarters is 2.9%. Despite that consistency, the average five-day price move after earnings is -2.05%, and the post-earnings drift is classified as “down.” That pattern is the classic “buy the rumor, sell the news” dynamic: expectations can run ahead of the actual release, and even a modest beat sometimes leaves sellers in control during the following week.

The most recent quarters illustrate the split personality. On August 4, 2026, the company reported $1.27 versus a $1.24 estimate, a 2.4% surprise, and the stock rose 0.54% the next day and 0.08% over the following five days. Before that, on May 5, 2026, EPS came in at $1.32 versus $1.20, a 10% surprise, yet the stock fell 2.6% the next day and 6.75% over the next five days. On February 24, 2026, the $1.34 actual versus $1.30 estimate (3.1% surprise) still produced a -1.73% next-day move and a -3.77% five-day drift. The November 4, 2025 quarter was an exception: $1.38 versus $1.27 (8.7% surprise) led to a 0.56% next-day gain and a 2.25% five-day gain. With the next report set for November 3, 2026, before the open and consensus at $1.36, the historical record suggests the reaction will depend less on whether the company beats and more on how the result compares to the market’s real expectation already built into the stock.

For a deeper dive into how sell-side and institutional models are interpreting these trends ahead of the November 3, 2026 report, readers should review the full institutional verdict on Henry Schein rather than relying on headline numbers alone.